Benzalkonium chloride foruse in treating conjunctivitis and/or covid-19
Methods for treating coronavirus disease 2019 (COVID-19), including at least one ocular manifestation of COVID-19, methods for treating conjunctivitis, and methods for reducing COVID-19 transmission comprising administering an effective amount of benzalkonium chloride are disclosed. Pharmaceutical compositions comprising benzalkonium chloride are also disclosed.
1 . A method for treating at least one ocular manifestation of coronavirus disease 2019 (COVID-19) comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of benzalkonium chloride, pheniramine maleate, and naphazoline HCl.
2 . The method of claim 1 , wherein the pharmaceutical composition comprises 0.001% (w/v) to 0.02% (w/v) benzalkonium chloride.
3 . The method of claim 1 , wherein the pharmaceutical composition comprises 0.01% (w/v) benzalkonium chloride.
4 . The method of claim 1 , wherein the pharmaceutical composition is the form of an eye drop, a suspension, a gel, an ointment, an injectable solution, or a spray.
5 . The method of claim 1 , wherein the pharmaceutical composition is topically administered.
6 . The method of claim 1 , wherein the pharmaceutical composition is administered to at least one eye of the subject.
7 . The method of claim 1 , wherein treating at least one ocular manifestation of COVID-19 comprises treating at least one disease or condition chosen from eye redness, conjunctivitis, keratoconjunctivitis, dry eye disease, blurred vision, conjunctival hyperaemia, ocular irritation, foreign body sensation, epiphora, eyelid edema, and chemosis.
8 . The method of claim 1 , wherein treating at least one ocular manifestation of COVID-19 comprises treating conjunctivitis.
9 . The method of claim 1 , wherein treating at least one ocular manifestation of COVID-19 comprises improving visual acuity.
10 . The method of claim 1 , wherein treating at least one ocular manifestation of COVID-19 comprises reducing eye redness, ocular irritation, or foreign body sensation.
11 . A method for reducing a risk of SARS-COV-2 ocular transmission comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of benzalkonium chloride, pheniramine maleate, and naphazoline HCl.
12 . The method of claim 11 , wherein the pharmaceutical composition comprises 0.001% (w/v) to 0.02% (w/v) benzalkonium chloride.
13 . The method of claim 11 , wherein the pharmaceutical composition comprises 0.01% (w/v) benzalkonium chloride.
14 . The method of claim 11 , wherein the pharmaceutical composition is the form of an eye drop, a suspension, a gel, an ointment, an injectable solution, or a spray.
15 . The method of claim 11 , wherein the pharmaceutical composition is topically administered.
16 . The method of claim 11 , wherein the pharmaceutical composition is administered to at least one eye of the subject.
17 . A method for preventing coronavirus disease 2019 (COVID-19) comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of benzalkonium chloride, pheniramine maleate, and naphazoline HCl.
18 . The method of claim 17 , wherein the pharmaceutical composition comprises 0.001% (w/v) to 0.02% (w/v) benzalkonium chloride.
19 . The method of claim 17 , wherein the pharmaceutical composition comprises 0.01% (w/v) benzalkonium chloride.
20 . The method of claim 17 , wherein the pharmaceutical composition is the form of an eye drop, a suspension, a gel, an ointment, an injectable solution, or a spray.
21 . The method of claim 17 , wherein the pharmaceutical composition is topically administered.
22 . The method of claim 17 , wherein the pharmaceutical composition is administered to at least one eye of the subject.
23 . A method for reducing an ocular SARS-COV-2 viral load comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of benzalkonium chloride, pheniramine maleate, and naphazoline HCl.
24 . The method of claim 23 , wherein the pharmaceutical composition comprises 0.001% (w/v) to 0.02% (w/v) benzalkonium chloride.
25 . The method of claim 23 , wherein the pharmaceutical composition comprises 0.01% (w/v) benzalkonium chloride.
26 . The method of claim 23 , wherein the pharmaceutical composition is the form of an eye drop, a suspension, a gel, an ointment, an injectable solution, or a spray.
27 . The method of claim 23 , wherein the pharmaceutical composition is topically administered.
28 . The method of claim 23 , wherein the pharmaceutical composition is administered to at least one eye of the subject.
29 . A method for reducing an intranasal SARS-COV-2 viral load comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of benzalkonium chloride, pheniramine maleate, and naphazoline HCl.
30 . The method of claim 29 , wherein the pharmaceutical composition comprises 0.001% (w/v) to 0.2% (w/v) benzalkonium chloride.
31 . The method of claim 29 , wherein the pharmaceutical composition comprises 0.005% (w/v) to 0.2% (w/v) benzalkonium chloride.
32 . The method of claim 29 , wherein the pharmaceutical composition comprises 0.005% (w/v) to 0.1% (w/v) benzalkonium chloride.
33 . The method of claim 29 , wherein the pharmaceutical composition comprises 0.01% (w/v) benzalkonium chloride.
34 . The method of 29 , wherein the pharmaceutical composition is the form of a spray.
35 . A method for treating or preventing coronavirus disease 2019 (COVID-19) comprising intranasally administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of benzalkonium chloride, pheniramine maleate, and naphazoline HCl.
36 . The method of claim 35 , wherein the pharmaceutical composition comprises 0.001% (w/v) to 0.2% (w/v) benzalkonium chloride.
37 . The method of claim 35 , wherein the pharmaceutical composition comprises 0.005% (w/v) to 0.2% (w/v) benzalkonium chloride.
38 . The method of claim 35 , wherein the pharmaceutical composition comprises 0.005% (w/v) to 0.1% (w/v) benzalkonium chloride.
39 . The method of claim 35 , wherein the pharmaceutical composition comprises 0.01% (w/v) benzalkonium chloride.
40 . The method of claim 35 , wherein the pharmaceutical composition is the form of a spray.